Amifostine promotes hemopoietic progenitor cell mobilization in patients with myelodysplastic syndrome

Anticancer Research

Volumn 22, Issue 3, 2002, Pages 1819-1824

  Arboscello, Eleonora ^a   Botta, Marco ^a   Lerza, Roberto ^a   Bogliolo, Giuseppe ^a   Clavio, Marino ^a   Miglino, Maurizio ^a   Mencoboni, Manlio ^a   Pannacciulli, Ivo ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Amifostine; Hematological malignancies; Hemopoietic progenitor cells; Myelodysplasia

Indexed keywords

AMIFOSTINE; HEMOGLOBIN;

AGED; ARTICLE; BLOOD; BONE MARROW; BURST FORMING UNIT E; CANCER CHEMOTHERAPY; CANCER GROWTH; CELL MOTILITY; CLINICAL ARTICLE; COLONY FORMING UNIT GM; DRUG ACTIVITY; FEMALE; HEMATOPOIESIS; HUMAN; LEUKOCYTE COUNT; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; RETICULOCYTE COUNT; STEM CELL; THROMBOCYTE COUNT;

AGED; AGED, 80 AND OVER; AMIFOSTINE; ERYTHROID PROGENITOR CELLS; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HUMANS; MALE; MYELODYSPLASTIC SYNDROMES;

EID: 0036324933     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Ex vivo manipulation of hematopoietic stem cells for trasplantation: The potential role of amifostine
2. Amifostine protects against early cisplatin-induced renal damages and enhances CD34+ cell numbers for PBSC collection
3. Poor response rate to a continuous schedule of amifostine therapy for low/intermediate risk' myelodysplastic patients
4. The growth of bone marrow cells in vitro
5. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine
6. Amifostine improves the antileukemic therapeutic index of mafosfamide: Implication for bone marrow purging
7. Effects of recombinant human granulocyte colony-stimulating factor on hemopoietic progenitor cells in cancer patients
8. Myelodysplasia
9. Effect of treatment with amifostine used as a single agent in patients with refractory anemia on clinical outcome and serum tumor necrosis factor alpha levels
10. The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects
11. Erythroid colony formation in cultures of mouse and human bone marrow: Analysis of the requirement for erythropoietin by gel filtration and affinity chromatography of agarose concanavalin
12. Phase II study of amifostine for the treatment of the myelodysplastic syndrome (MDS)
13. Amifostine suppresses apoptosis in myelodysplastic CD34+ cells and promotes progenitor growth via polyamine-like effects
14. Chemoprotectants: A review of their clinical pharmacology and therapeutic efficacy
15. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome
16. Pharmacological differentiation and anti-apoptotic therapy in myelodysplastic syndromes
17. Amifostine stimulates formation of multipotent and erythroid bone marrow progenitors
18. 'Tunel' evidence of reduced bone marrow cell apoptosis in a refractory anaemia patient treated with amifostine
19. Homing and trafficking of hematopoietic progenitor cells
20. Oxidative DNA damage in CD34+ myelodysplastic cells is associated with intracellular redox changes and elevated plasma tumour necrosis factor-cc concentration
21. Apoptosis in bone marrow biopsy sample involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes
22. Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone
23. Stem cell migration and proliferation during severe anemia
24. Amifostine cytotoxicity and introduction of apoptosis in a human myelodysplastic cell line
25. Myeloid stem cell kinetics during erythropoietic stress
26. Peripheral blood mobilization of hematopoietic stem cells: Cytokine-mediated regulation of adhesive interactions within the hematopoietic microenvironment
27. Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man
28. Amifostine. A review of its pharmaco-dynamic and pharmacokinetics properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector
29. Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cell is maintained
30. Haemopoietic progenitor homing and mobilization